- Home
- NHI vs AKRO Comparison
NHI vs AKRO Comparison
Compare NHI & AKRO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NHI
- AKRO
- Stock Information
- Founded
- NHI 1991
- AKRO 2017
- Country
- NHI United States
- AKRO United States
- Employees
- NHI N/A
- AKRO N/A
- Industry
- NHI Real Estate Investment Trusts
- AKRO Biotechnology: Pharmaceutical Preparations
- Sector
- NHI Real Estate
- AKRO Health Care
- Exchange
- NHI Nasdaq
- AKRO Nasdaq
- Market Cap
- NHI 3.7B
- AKRO 3.7B
- IPO Year
- NHI 1991
- AKRO 2019
- Fundamental
- Price
- NHI $76.80
- AKRO $54.04
- Analyst Decision
- NHI Buy
- AKRO Buy
- Analyst Count
- NHI 4
- AKRO 10
- Target Price
- NHI $82.75
- AKRO $73.56
- AVG Volume (30 Days)
- NHI 210.3K
- AKRO 2.1M
- Earning Date
- NHI 11-06-2025
- AKRO 11-07-2025
- Dividend Yield
- NHI 4.79%
- AKRO N/A
- EPS Growth
- NHI 8.88
- AKRO N/A
- EPS
- NHI 3.17
- AKRO N/A
- Revenue
- NHI $357,572,000.00
- AKRO N/A
- Revenue This Year
- NHI $4.68
- AKRO N/A
- Revenue Next Year
- NHI $10.60
- AKRO N/A
- P/E Ratio
- NHI $24.24
- AKRO N/A
- Revenue Growth
- NHI 8.40
- AKRO N/A
- 52 Week Low
- NHI $65.13
- AKRO $21.34
- 52 Week High
- NHI $82.32
- AKRO $58.40
- Technical
- Relative Strength Index (RSI)
- NHI 54.79
- AKRO 67.29
- Support Level
- NHI $74.87
- AKRO $53.90
- Resistance Level
- NHI $76.46
- AKRO $54.31
- Average True Range (ATR)
- NHI 1.85
- AKRO 0.23
- MACD
- NHI 0.24
- AKRO -0.25
- Stochastic Oscillator
- NHI 73.25
- AKRO 66.30
About NHI National Health Investors Inc.
National Health Investors Inc is a housing and medical facility REIT. The company operates through two reportable segments, i.e., Real Estate Investments and Senior Housing Operating Portfolio (SHOP). The Real Estate Investments segment, which generates maximum revenue, consists of real estate investments and leases, mortgages, and other notes receivables in independent living facilities, assisted living facilities, entrance fee communities, senior living campuses, skilled nursing facilities, and a hospital. The SHOP segment is comprised of two ventures that own the operations of independent living facilities. The company's revenues are derived in the form of rental income, mortgage and other notes receivable interest income, and resident fees and services.
About AKRO Akero Therapeutics Inc.
Akero Therapeutics Inc is a clinical-stage biotechnology company focused on developing and commercializing transformative treatments for serious metabolic diseases with high unmet medical needs. Its focus is nonalcoholic steatohepatitis (MASH), or NASH, a disease without any approved therapies. The company's product candidate efruxifermin is an FGF21 analog with properties that have the potential to address the core processes underlying NASH pathogenesis.